Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction Of Myelosuppression In Mouse Model Of Chemotherapy

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612’s ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX). Michael Fonstein, Ph.D.

More: continued here

Filed under: Cancer on October 29th, 2008